Robert F. Kennedy Jr had an absolute trainwreck of a confirmation hearing. Kennedy, who had been a vocal vaccine skeptic and preached numerous disproven conspiracy theories, was lambasted for his anti-science stance and his refusal to stop suing the very companies he now wants to regulate.

A recent lightning rod for abortion opponents, the drug mifepristone—the first of two in the standard medication abortion regimen—surfaced several times during Robert F. Kennedy, Jr.’s first Senate confirmation hearing as President Trump’s pick for Health and Human Services secretary.

Missouri, Kansas and Idaho can press forward with their lawsuit to restrict access to the abortion drug mifepristone, a federal judge ruled Thursday, months after the US Supreme Court had rejected an earlier version of the legal challenge.

Last Friday, my colleague Julianne McShane and I broke the news of a pair of letters sent by 30 prominent anti-abortion movement leaders to the heads of the Departments of Health and Human Services and Justice, asking them to use the powers of their agencies to attack abortion pills.

Three Republican-led states will be allowed to move forward with a lawsuit to restrict access to mifepristone, a Texas federal judge ruled Thursday, months after the Supreme Court rejected an

Meanwhile, in an executive order, Trump created his long-discussed “Department of Government Efficiency,” to be led by Elon Musk, the world’s richest man. On paper, the department is tasked with modernizing federal technology and software; however, Trump and Musk have spent months boasting about how it will gut the federal government.

A higher dose of an emergency-contraception drug may open a back door for Americans seeking abortions in restrictive states.

Robert F. Kennedy Jr. made several disturbing comments during his first Senate confirmation hearing Wednesday suggesting that, as Donald Trump’s secretary of health and human services, he’s hoping to limit access to the abortion pill mifepristone.

A new study shows a possible new abortion drug to replace mifepristone. But will these results increase abortion access—or restrict women's reproductive health options down the line?

The Biden administration had defended the FDA’s regulatory approach to mifepristone at the Supreme Court last year. The Trump transition team did not respond to a CNN inquiry about the case.

Several states are trying to curtail abortion medication by claiming mifepristone could contaminate drinking water.